No Data
Wuhan Keqian Biology Co., Ltd. (688526.SH): has repurchased 0.4084% of the company's shares.
On September 2nd, Keqian Biology (688526.SH) announced that as of August 31, 2024, the company has repurchased a total of 1,903,866 shares of the company's stock through the Shanghai Stock Exchange trading system through centralized bidding trading method, accounting for 0.4084% of the company's total share capital of 466,128,056 shares. The highest price of the repurchase transaction was 18.90 yuan/share, and the lowest price was 13.48 yuan/share, with a total payment of RMB 31,618,428.15 (excluding stamp duty, transaction commission, and other transaction costs).
Wuhan Keqian Biology Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Wuhan Keqian Biology Co., Ltd.
Wuhan Keqian Biology Co., Ltd. (688526.SH): Net income in the first half of the year was 0.15 billion yuan, a year-on-year decrease of 36.19%.
On August 29, Keqian Biology (688526.SH) announced its semi-annual report. The company achieved a revenue of 0.4 billion yuan, a year-on-year decrease of 24.69%; the net income attributable to the parent company was 0.15 billion yuan, a year-on-year decrease of 36.19%. During the reporting period, the company continued to increase its investment in research and development, with research and development expenses of 40.3594 million yuan, effectively ensuring the continuous and efficient development of new vaccine research and production technology. From January to June 2024, the company obtained a class 1 new drug - porcine coronavirus inactivation vaccine (CHN-HN-2014 strain) and Porcine Circovirus type 2.
Wuhan Keqian Biology Co., Ltd (688526.SH) released its semi-annual performance with a net income of 0.153 billion yuan, a year-on-year decrease of 36.19%.
wuhan keqian biology co.,ltd (688526.SH) disclosed the semi-annual report for 2024, during the reporting period the company achieved revenue of 4.01...
Wuhan Keqian Biology Co., Ltd. (688526.SH) has repurchased 0.4084% of its shares.
On July 31st, Gelonhui reported that Wuhan Keqian Biology Co., Ltd. (688526.SH) has cumulatively repurchased 1,903,866 shares of the company's stock through the Shanghai Stock Exchange trading system by centralized bidding trading method as of July 31, 2024, accounting for 0.4084% of the company's total share capital of 466,128,056 shares. The highest transaction price for the repurchase was 18.90 yuan/share, the lowest price was 13.48 yuan/share, and the total amount paid was RMB 31,618,428.15 (excluding stamp duty, transaction fees, and other trading expenses).
No Data
